A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments

Author： Masui Kenta  

Publisher： Oxford University Press

ISSN： 1460-2180

Source： Carcinogenesis, Vol.34, Iss.4, 2013-04, pp. : 725-738

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trials and tribulations of cytotoxic and targeted breast cancer therapy: a clinical perspective on the next phase of progress

By Twelves Chris  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 3, 2013-03 ,pp. : 251-255

Informa Healthcare

Access to resources Recommend Favorite

Next-generation sequencing for lung cancer

By Wu Kehua   Huang R Stephanie   House Larry   Cho William Chi  

Future Oncology, Vol. 9, Iss. 9, 2013-09 ,pp. : 1323-1336

Future Medicine

Access to resources Recommend Favorite

Molecularly Targeted Therapy in Breast Cancer: The New Generation

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 3, Iss. 2, 2008-06 ,pp. : 100-104

Bentham Science Publishers

Access to resources Recommend Favorite

Mechanisms of mTOR inhibitor resistance in cancer therapy

By Carew Jennifer  

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 17-27

Springer Publishing Company

Access to resources Recommend Favorite

Enhancing Next‐Generation Sequencing‐Guided Cancer Care Through Cognitive Computing

By  

The Oncologist, Vol. 23, Iss. 2, 2018-02 ,pp. : 179-185

John Wiley & Sons Inc

Access to resources Recommend Favorite